56 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling.
The University Of Queensland
Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core.
Vanderbilt University
Synthesis and Pharmacological Characterization of Novel Glucagon-like Peptide-2 (GLP-2) Analogues with Low Systemic Clearance.
Ferring Research Institute
A new GLP-1 analogue with prolonged glucose-lowering activity in vivo via backbone-based modification at the N-terminus.
Peking University
Cyclic alpha-conotoxin peptidomimetic chimeras as potent GLP-1R agonists.
The University Of Queensland
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Novo Nordisk
Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists.
University Of Queensland
Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists.
Dainippon Sumitomo Pharma
Discovery of (S)-2-cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (GLP-1R) positive allosteric modulator (PAM).
Vanderbilt University School Of Medicine
The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.
Merck Research Laboratories
A general method for making peptide therapeutics resistant to serine protease degradation: application to dipeptidyl peptidase IV substrates.
Tufts University
The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.
Pfizer
Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-ß-alanine (MK-0893) for the treatment of type II diabetes.
Merck Research Laboratories
Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.
Bristol-Myers Squibb
A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.
Pfizer
Discovery of N-aryl-2-acylindole human glucagon receptor antagonists.
Merck Research Laboratories
Discovery of cyclic guanidines as potent, orally active, human glucagon receptor antagonists.
Merck Research Laboratories
Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.
Merck Research Laboratories
Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges.
University Of Texas At Dallas
Identification of glycosylated exendin-4 analogue with prolonged blood glucose-lowering activity through glycosylation scanning substitution.
Shionogi And
Search for alpha-helical propensity in the receptor-bound conformation of glucagon-like peptide-1.
University Of Texas At Dallas
Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1.
Tufts University
Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.
Novo Nordisk
Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity.
Amgen
Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor.
Pfizer
New beta-alanine derivatives are orally available glucagon receptor antagonists.
Novo Nordisk
Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists.
Merck Research Laboratories
Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog.
Conjuchem
Design, synthesis and biological evaluation of double fatty chain-modified glucagon-like peptide-1 conjugates.
Fudan University School Of Pharmacy
Optimization of Truncated Glucagon Peptides to Achieve Selective, High Potency, Full Antagonists.
Indiana University
Rational design and biological evaluation of gemfibrozil modified Xenopus GLP-1 derivatives as long-acting hypoglycemic agents.
Jiangnan University
Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.
Syracuse University
Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins.
Schrodinger
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.
Novo Nordisk
Novel lipid side chain modified exenatide analogs emerged prolonged glucoregulatory activity and potential body weight management properties.
China Pharmaceutical University
Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors.
Sosei Heptares
Natural dimers of coumarin, chalcones, and resveratrol and the link between structure and pharmacology.
Nagasaki International University
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
Shanghaitech University
Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R).
Sanofi-Aventis Deutschland
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Terns Pharmaceuticals
Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates.
China Pharmaceutical University
Novel fatty acid chain modified GLP-1 derivatives with prolonged in vivo glucose-lowering ability and balanced glucoregulatory activity.
China Pharmaceutical University
Optimization of peptide-based polyagonists for treatment of diabetes and obesity.
Novo Nordisk Research Center Indianapolis
A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.
China Pharmaceutical University
Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists Specifically Optimized for Multidose Formulations.
Sanofi-Aventis Deutschland
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
Sanofi-Aventis Deutschland